Adjuvant Systemic Therapy for Breast Cancer Patients Without Lymph Node Metastases (N-)

  • A. Goldhirsch
  • R. D. Gelber
Part of the ESO Monographs book series (ESO MONOGRAPHS)


Several issues have recently been raised with respect to the treatment of patients diagnosed as having no axillary metastases after removal of breast cancer and axillary clearance. Patients with N- disease who were treated in the more recent controlled clinical trials have higher relapse rates than those entered in the earlier series from which our perception of prognosis for these patients has been derived. This could be due to a reporting bias, to a selection of patients for study who have a worse prognosis, or because the prognosis for N- breast cancer patients in general has in fact changed from what it was a decade or so ago.

A second important issue is the fact that major trials using either systemic endocrine therapy or chemotherapy have yielded significant improvement in terms of disease-free survival. Adjuvant therapy policies — particularly those affecting women who elect not to be treated within the framework of a clinical trial — are once again in a state of re-evaluation. This summary makes the point that women with N- breast cancer should be treated within clinical trials because the many factors which must be considered for therapy decision-making can most efficaciously be assessed within such a framework.


Breast Cancer Breast Cancer Patient Adjuvant Therapy Operable Breast Cancer Adjuvant Systemic Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Harris JR, Henderson IC: Natural history and staging of breast cancer. In: Harris JR, Hellman S, Henderson IC, Kinne DW eds Breast Diseases. JB Lippincott Co, Philadelphia 1987 pp 233–258Google Scholar
  2. 2.
    UK Trial of Early Detection of Breast Cancer Group. First results on mortality reduction in the UK trial of early detection of breast cancer. Lancet 1988 (10): 411–416Google Scholar
  3. 3.
    Ludwig Breast Cancer Study Group: Randomized perioperative therapy in operable breast cancer: the Ludwig Study V. Proc of the 3rd Conference on Adjuvant Therapy of Primary Breast Cancer. St Gallen 1988 p 8Google Scholar
  4. 4.
    Valagussa P, Bonadonna G, Veronesi U: Patterns of relapse and survival in operable breast carcinoma with positive and negative axillary nodes. Tumori 1978 (64): 241–258PubMedGoogle Scholar
  5. 5.
    Valagussa P, Bignami P, Buzzoni R et al: Are estrogen receptors alone a reliable prognostic factor in node-negative breast cancer? In: Jones SE and Salmon SE eds Adjuvant Therapy of Cancer IV. Grune & Stratton, Orlando 1984 pp 407–415Google Scholar
  6. 6.
    Veronesi U, Saccozzi R, DelVecchio M et al: Comparing radical mastectomy with quadrantectomy, axillary dissection and radiotherapy in patients with small cancer of the breast. N Engl J Med 1981 (305): 6–11PubMedCrossRefGoogle Scholar
  7. 7.
    Fisher B, Slack N, Katrych D et al: Ten-year follow-up results of patients with carcinoma of the breast in a cooperative trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet 1975 (140): 528–534PubMedGoogle Scholar
  8. 8.
    Fisher ER, Sass R, Fisher B: Pathological findings from the National Surgical Adjuvant Project for Breast Cancer protocol #4. Cancer 1984 (53): 712–723PubMedCrossRefGoogle Scholar
  9. 9.
    Fisher B, Bauer M, Margolese R et al: Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med 1985 (312): 665–670PubMedCrossRefGoogle Scholar
  10. 10.
    Valagussa P, Bonadonna G, Veronesi U: Patterns of relapse and survival following radical mastectomy. Cancer 1978 (41): 1170–1178PubMedCrossRefGoogle Scholar
  11. 11.
    Nemoto T, Vana J, Bedwani RN et al: Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer 1980 (45): 2917–2924PubMedCrossRefGoogle Scholar
  12. 12.
    Handley RS: Carcinoma of the breast. Ann R Coll Surg Engl 1975 (57): 59–66PubMedGoogle Scholar
  13. 13.
    Veronesi U, Cascinelli N, Greco M et al: Prognosis of breast cancer patients after mastectomy and dissection of internal mammary nodes. Ann Surg 1985 (202): 702–707PubMedCrossRefGoogle Scholar
  14. 14.
    Bloom HJG and Field JR: Impact of tumor grade and host resistance on survival of women with breast cancer. Cancer 1971 (28): 1580–1589PubMedCrossRefGoogle Scholar
  15. 15.
    Tubiana M, Pejovic MN, Chavandra N et al: The long term prognostic significance of the thymidine labeling index in breast cancer. Int J Cancer 1984 (30): 441–445CrossRefGoogle Scholar
  16. 16.
    Silvestrini R, Daidone MG and Gasparini G: Cell kinetics as a prognostic marker in node-negative breast cancer. Cancer 1985 (56): 1982–1987PubMedCrossRefGoogle Scholar
  17. 17.
    Dressler LG, Seamer LC, Owen MA et al: DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens. Cancer 1988 (61): 420–427PubMedCrossRefGoogle Scholar
  18. 18.
    William MR, Todd JH, Ellis IO et al: Oestrogen receptors in primary and advanced breast cancer: an eight year review of 706 cases. Br J Cancer 1986 (55): 67CrossRefGoogle Scholar
  19. 19.
    Fisher B, Redmond C, Fisher ER et al: Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node-negative breast cancer patients: Findings from the NSABP protocol B-06. J Clin Oncol 1988 (6):1076–1087Google Scholar
  20. 20.
    Ludwig Breast Cancer Group: Ludwig Trial V Results unpublishedGoogle Scholar
  21. 21.
    McGuire WL: The risk of recurrence in breast cancer patients. In: Proc of the 3rd International Conference on Adjuvant Therapy of Primary Breast Cancer. St Gallen 1988 p 19Google Scholar
  22. 22.
    Gullick WJ, Berger MS, Bennett PLP et al: Expression of the c-erbB-2 protein in normal and transformed cells. Int J Cancer 1987 (40): 246–254PubMedCrossRefGoogle Scholar
  23. 23.
    Hynes NE, Berger M, Locher G et al: Analysis of the c-erbB-2 proto-oncogene in human breast carcinomas: correlation of gene amplification, protein expression and clinical parameters. In: Proc of the 3rd International Conference on Adjuvant Therapy of Primary Breast Cancer. St Gallen 1988 p 4Google Scholar
  24. 24.
    Hovus AG, Rutter RVP, Berg JW: Significance of axillary macrometastases and micrometastases in mammary cancer. Ann Surg 1971 (173): 44–46CrossRefGoogle Scholar
  25. 25.
    Fisher ER, Swamidoss S, Lee CH et al: Detection and significance of occult axillary node metastases in patients with invasive breast cancer. Cancer 1978 (42): 2025–2031PubMedCrossRefGoogle Scholar
  26. 26.
    Rosen PP, Saigo PE, Brown DW Jr et al: Prognosis in stage II T1 N1 M0 breast cancer. Ann Surg 1981 (194): 576–581PubMedCrossRefGoogle Scholar
  27. 27.
    Benchabbat A, Friedman S, Mouziesse H et al: Clandestine metastasis of breast axillary lymph nodes: A finding confirming worse prognosis than standard nodal metastasis. In: Proc ECCO 4, Madrid 1987 p113Google Scholar
  28. 28.
    Nissen-Meyer R, Kjellgren K, Malmio K et al: Surgical adjuvant chemotherapy. Results with one short course of cyclophosphamide after mastectomy for breast cancer. Cancer 1978 (41): 2088–2098PubMedCrossRefGoogle Scholar
  29. 29.
    Nolvadex Adjuvant Trial Organisation: Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Br J Cancer 1988 (57): 608–611CrossRefGoogle Scholar
  30. 30.
    Scottish Cancer Trials Office: Adjuvant tamoxifen in the management of operable breast cancer. The Scottish trial. Lancet 1987 (11): 171–175Google Scholar
  31. 31.
    CRC Adjuvant Breast Trial Working Party. Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. Br J Cancer 1988 (57): 604–607CrossRefGoogle Scholar
  32. 32.
    Senn HJ, Jungi WF, Amgwerd R et al: Swiss adjuvant trial OSAKO 06/74 with chlorambucil, methotrexate and 5-fluorouracil plus BCG in node-negative breast cancer patients: five-year results. NCI Monographs 1986 (1): 129–134PubMedGoogle Scholar
  33. 33.
    Morrison JM, Howell A, Grieve RJ et al: The West Midlands Oncology Association trials on adjuvant chemotherapy for operable breast cancer. In: Salmon SE ed: Adjuvant Therapy of Cancer V. Grune & Stratton, Orlando 1987 pp 311–318Google Scholar
  34. 34.
    Caffier H, Rotte K, Haeggqwist O: Adjuvant chemotherapy versus postoperative irradiation in node-negative breast cancer. In: Jones SE and Salmon SE eds Adjuvant Therapy of Cancer IV. Grune & Stratton, Orlando 1984 pp 417–424Google Scholar
  35. 35.
    Jakesz R, Kolb R, Reiner G et al: Adjuvant chemotherapy in node-negative breast cancer patients. In: Salmon SE ed: Adjuvant Therapy of Cancer V. Grune & Stratton, Orlando 1987 pp 223–231Google Scholar
  36. 36.
    Williams CJ, Buchanan RB, Hall V et al: Adjuvant chemotherapy for T1_2, N1, M0 estrogen receptor negative breast cancer: preliminary results of a randomized trial. In: Salmon SE ed: Adjuvant Therapy of Cancer V. Grune & Stratton, Orlando 1987 pp 233–241Google Scholar
  37. 37.
    Bonadonna G, Valagussa P, Zambetti M et al: Milan adjuvant trials for stage I-II breast cancer. In: Salmon SE ed: Adjuvant Therapy of Cancer V. Grune & Stratton, Orlando 1987 pp 211–221Google Scholar
  38. 38.
    NEWS FROM NCI: Treatment alert issues for node- negative breast cancer. JNCI 1988 (80): 550–551Google Scholar
  39. 39.
    Goldhirsch A, Gelber RD, Simes RJ et al: Costs and benefits of adjuvant therapy in breast cancer: a quality adjusted survival analysis. J Clin Oncol 1989 (in press)Google Scholar
  40. 40.
    Gelber RD, Goldhirsch A: Can a clinical trial be the treatment of choice for patients with cancer? JNCI 1988 (80): 886–887PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • A. Goldhirsch
    • 1
  • R. D. Gelber
    • 2
  1. 1.Division of OncologyOspedale San Giovanni, Bellinzona and Ospedale CivicoLuganoSwitzerland
  2. 2.Harvard School of Public Health and Dana-Farber Cancer InstituteBostonUSA

Personalised recommendations